Celebrating Success in the Pharmaceuticals Industry: Jazz Pharmaceuticals Enters Deal With Redx

HGF would like to congratulate Redx Pharmaceuticals on their recent deal with Jazz Pharmaceuticals concerning the global rights to Redx’s KRAS Inhibitor Program.

This partnership has the potential to provide innovative new cancer treatments that address a currently unmet medical need through the development of KRAS inhibitors.

Redx received a $10 million payment and is potentially entitled to up to a further £870 million of milestone payments. Additionally, Redx stands to receive royalties on product sales, should the collaboration give rise to a marketed drug product.

This deal confirms Redx’s reputation as a UK leader in the field of drug discovery and development.  Redx have a terrific track record of designing potential drug molecules.

At HGF, we take great pride in assisting Redx in obtaining strong, dynamic IP portfolios that protect their assets, and which play a crucial role in securing partnerships and driving innovation. We look forward to seeing the positive impact of this alliance and the potential breakthroughs it may bring.

Click the button below to find out more.